Search
01/08/2025
Balance Assessment in Patients With Peripheral Neuropathies Using Digital Biomechanical Biomarkers
Illa, CT, Pegueroles, J, Claramunt-Molet, M, Pi-Cervera, A, Heras-Delgado, A, Gascón-Fontal, J, Idelsohn-Zielonka, S, Rico, M, Vidal, N, Martín-Aguilar, L, Caballero-Avila, M, Lleixà, C, Collet-Vidiella, R, Llarch, P, Llansó, L, Carbayo-Viejo, A, Vesperinas, A, Querol, L, Pascual-Goñi, E. Balance Assessment in Patients With Peripheral Neuropathies Using Digital Biomechanical Biomarkers. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025
Exploratory Biomarker Analyses in a Phase 2 Trial of Riliprubart for Chronic Inflammatory Demyelinating Polyneuropathy
Querol, L, Hourcade, S, Chow, T, Chen, Y, Levit, M, Hammond, TR, Kramer, ML, Ternes, N, Seluzhytsky, A, Alonso-Alonso, M, Atassi, N, Lewis, RA. Exploratory Biomarker Analyses in a Phase 2 Trial of Riliprubart for Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025
ADHERE plus Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy
Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Pinter, GL, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, Van Doorn, PA, Lewis, RA. ADHERE plus Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025
Safety and Efficacy of Riliprubart in CIDP: 76-Week Phase 2 Trial Results
Querol, L, Lewis, RA, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. Safety and Efficacy of Riliprubart in CIDP: 76-Week Phase 2 Trial Results. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025
Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study
Querol, L, Harbo, T, Peric, S, Hussain, Y, Cadour, S, Van de Walle, I, Persson, E, Vujcic, M, Van de Steen, O, Allen, J, Nobile-Orazio, E, Attarian, S, Karam, C, Katzberg, H, Stettner, M, Rinaldi, S, van der Pol, WL. Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2025
Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study
Hewamadduma, C, Peric, S, Claeys, K, Querol, L, Altamimi, S, Van de Walle, I, Persson, E, Van Hoomissen, I, Szmyd, G, Vujcic, M, Cadour, S, Van de Steen, O, Arvin-Berod, C, Allen, J. Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).